首页> 外文会议>International Symposium of Biomedical Engineering >Free Published Online: 13 February 2018 Preparation and characterization of cross-linked excipient of coprocessed xanthan gum-acacia gum as matrix for sustained release tablets
【24h】

Free Published Online: 13 February 2018 Preparation and characterization of cross-linked excipient of coprocessed xanthan gum-acacia gum as matrix for sustained release tablets

机译:在线免费发布于:2018年2月13日,将共合的黄原胶 - 金合欢胶交联赋形剂的制备及表征作为持续释放片剂的基质

获取原文

摘要

Sustained release tablet is solid dosage form which is designed to release drugs slowly in the body. This research was intended to prepare and characterize the cross-linked excipients of co-processed xanthan gum-acacia gum (CL-Co-XGGA) as matrices for sustained release tablets with gliclazide as a model drug. CL-Co-XGGA excipients were cross-linked materials of co-processed excipients of xanthan gum-acacia gum (Co-XGGA) using sodium trimetaphosphate. Co-processed excipients of xanthan gum-acacia gum were prepared in the ratio of each excipient 1:2, 1:1 and 2:1. Co-XGGA and CL-Co-XGGA excipients were characterized physically, chemically and functionally. Then, the sustained release (SR) tablets were formulated by wet granulation method using CL-Co-XGGA excipients as matrices. Also, the dissolution study of the gliclazide SR tablets was carried out in phosphate buffer medium pH 7,4 containing sodium lauryl sulphate 0.2% for 12 hours. The results showed that the degree of substitution (DS) of CL-Co-XGGA 1:2, 1:1, 2:1 excipients were respectively 0.067, 0.082 and 0.08. Besides that, the excipients gel strengths were 14.03, 17.27 and 20,70 gF, respectively. The cross-linked excipients had improved flow properties and swelling capability compared to the Co-XGGA excipients. The results of the gliclazide SR tablets evaluations showed that all tablets were passed all tablet requirements. Moreover, the gliclazide release from SR tablets F1 - F6 revealed the sustained release profile, which was following zero order kinetics (F1, F2, F3, F6) and Higuchi kinetics (F4 and F5). It could be concluded that the obtained CL-Co-XGGA excipients might be used as matrices for sustained release tablets and could retard drug release up to 8 until 32 hours.
机译:持续释放片剂是固体剂型,设计用于慢慢释放在体内的药物。该研究旨在制备和表征共处理的黄原胶 - 胶(Cl-Co-XGGA)的交联赋形剂作为具有Gliclazide作为模型药物的持续释放片剂的基质。 Cl-Co-XGGA赋形剂是使用三磷酸钠的黄原胶 - 胶(Co-XGGA)的共加工赋形剂的交联材料。以每种赋形剂1:2,1:1和2:1的比例制备黄原胶胶的共处理赋形剂。 CO-XGGA和CL-CO-XGGA赋形剂在物理上,化学和功能性地表征。然后,使用Cl-Co-XGGA赋形剂作为基质,通过湿造粒方法配制持续释放(SR)片剂。此外,Gliclazide SR片剂的溶出研究在含有十二烷基硫酸钠钠0.2%持续12小时的磷酸盐缓冲培养基pH 7,4中进行。结果表明,Cl-Co-XGGA 1:2,1:1,2:1赋形剂的取代度(DS)分别为0.067,0.082和0.08。此外,赋形剂凝胶强度分别为14.03,17.27和20,70gF。与CO-XGGA赋形剂相比,交联赋形剂具有改善的流动性能和溶胀能力。 Gliclazide SR片剂评估结果表明,所有片剂都通过所有片剂要求。此外,来自Sr片剂F1-F6的Gliclazide释放揭示了持续释放曲线,其归零动力学(F1,F2,F3,F6)和HIGUCHI动力学(F4和F5)。可以得出结论,获得的Cl-Co-XGGA赋形剂可用作持续释放片剂的基质,并且可以将药物释放延迟高达8至32小时。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号